Controversies in circulating tumor cell count during therapy

Expert Review of Molecular Diagnostics

Volumn 13, Issue 5, 2013, Pages 499-507

  Raimondi, Cristina ^a   Gradilone, Angela ^a   Gazzaniga, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

circulating tumor cells; heterogeneity; personalized medicine

Indexed keywords

BIOLOGICAL MARKER;

BIOPSY; BLOOD CELL COUNT; BREAST METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CIRCULATING TUMOR CELL; CIRCULATING TUMOR CELL COUNT; DECISION MAKING; DISEASE MARKER; HUMAN; LIQUID BIOPSY; MOLECULAR BIOLOGY; PATIENT INFORMATION; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR BIOPSY; VALIDATION PROCESS;

BIOPSY; CELL COUNT; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879344685     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.33     Document Type: Review

References (45)

1. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010, 617421 (2010).
2. Parkinson DR, Dracopoli N, Petty BG et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 10, 138 (2012).
3. Gorges TM, Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol. Immunother. 62(5), 931-939 (2013).
4. Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progressionfree and overall survival. Clin. Cancer Res. 12(14 Pt 1), 4218-4224 (2006).
5. Bertos NR, Park M. Breast cancer-one term, many entities? J. Clin. Invest. 121(10), 3789-3796 (2011).
6. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
7. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
8. Giordano A, Giuliano M, De Laurentiis M et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. 23(5), 1144-1150 (2012).
9. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 23(3), 618-624 (2012).
10. Wallwiener M, Hartkopf AD, Baccelli I et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res. Treat. 137(2), 503-510 (2013).
11. Yu M, Bardia A, Wittner BS et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119), 580-584 (2013).
12. Mego M, De Giorgi U, Dawood S et al. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int. J. Cancer 129(2), 417-423 (2011).
13. Gazzaniga P, Raimondi C, Gradilone A et al. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. Ann. Oncol. 22(8), 1929-1930 (2011).
14. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann. Oncol. 21(9), 1765-1771 (2010).
15. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol. Ther. 11(8), 714-723 (2011).
16. Conley SJ, Gheordunescu E, Kakarala P et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl Acad. Sci. USA 109(8), 2784-2789 (2012).
17. Müller V, Riethdorf S, Rack B et al.; on behalf of the DETECT study group. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 14(4), R118 (2012).
18. Nishino M, Jagannathan JP, Krajewski KM et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapyspecific response criteria to complement pitfalls of RECIST. AJR. Am. J. Roentgenol. 198(4), 737-745 (2012).
19. De Giorgi U, Mego M, Rohren EM et al. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J. Nucl. Med. 51(8), 1213-1218 (2010).
20. Fizazi K, Scher HI, Molina A et al.; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 13(10), 983-992 (2012).
21. Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol. 61(3), 549-559 (2012).
22. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin. Cancer Res. 17(12), 3903-3912 (2011).
23. Bidard FC, Hajage D, Bachelot T et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 14(1), R29 (2012).
24. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2), 275-292 (2011).
25. Pestrin M, Bessi S, Puglisi F et al. Final results of a multicenter Phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat. 134(1), 283-289 (2012).
26. Riethdorf S, Müller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16(9), 2634-2645 (2010).
27. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
28. Gasch C, Bauernhofer T, Pichler M et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59(1), 252-260 (2013).
29. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008).
30. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29(12), 1508-1511 (2011).
31. Barrière G, Tartary M, Rigaud M. Epithelial-mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol. 2012, 382010 (2012).
32. Weiss L. Metastatic inefficiency. Adv. Cancer Res. 54, 159-211 (1990).
33. Bonnomet A, Brysse A, Tachsidis A et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J. Mammary Gland Biol. Neoplasia 15(2), 261-273 (2010).
34. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11(4), R46 (2009).
35. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial-mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105(9), 1338-1341 (2011).
36. Armstrong AJ, Marengo MS, Oltean S et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 9(8), 997-1007 (2011).
37. Yokobori T, Iinuma H, Shimamura T et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73(7), 2059-2069 (2013).
38. Raimondi C, Gradilone A, Naso G et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 130(2), 449-455 (2011).
39. Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 79(4), 195-208 (2012).
40. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer Biol. 22(3), 194-207 (2012).
41. Chui MH. Insights into cancer metastasis from a clinicopathologic perspective: epithelial-mesenchymal transition is not a necessary step. Int. J. Cancer 132(7), 1487-1495 (2013).
42. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750-2767 (2011).
43. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and nonbasal-like triple-negative breast cancer. Oncologist 18(2), 123-133 (2013).
44. AJCC Cancer Staging Manual (7th Edition). Edge SB, Byrd DR, Compton CC et al. (Eds). Springer, New York, NY, USA, 347-376 (2010).
45. Gazzaniga P, Gradilone A, de Berardinis E et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann. Oncol. 23(9), 2352-2356 (2012).